Mediwound (NASDAQ:MDWD) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Mediwound (NASDAQ:MDWD) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. Zacks Investment Research currently has $2.25 price objective on the biopharmaceutical company’s stock.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Separately, Oppenheimer assumed coverage on shares of Mediwound in a research note on Monday. They set a buy rating and a $7.00 price target on the stock.

MDWD traded up $0.02 on Thursday, reaching $2.02. The company had a trading volume of 60,030 shares, compared to its average volume of 67,658. The business has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $2.56. The company has a market cap of $53.79 million, a price-to-earnings ratio of 8.42 and a beta of 1.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.28 and a current ratio of 3.43. Mediwound has a 52-week low of $1.44 and a 52-week high of $4.65.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The firm had revenue of $4.44 million for the quarter, compared to the consensus estimate of $4.25 million. Mediwound had a net margin of 18.46% and a negative return on equity of 71.14%. As a group, equities research analysts predict that Mediwound will post -0.37 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN increased its stake in shares of Mediwound by 15.8% in the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 29,911 shares during the period. Fortis Advisors LLC purchased a new position in shares of Mediwound in the first quarter worth $108,000. Sargent Investment Group LLC increased its stake in shares of Mediwound by 51.5% in the first quarter. Sargent Investment Group LLC now owns 117,400 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 39,900 shares during the period. Acadian Asset Management LLC increased its stake in shares of Mediwound by 136.4% in the first quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 75,045 shares during the period. Finally, UBS Group AG increased its stake in shares of Mediwound by 203.3% in the fourth quarter. UBS Group AG now owns 9,566 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 6,412 shares during the period. 23.93% of the stock is currently owned by hedge funds and other institutional investors.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.